



Cancer Metabolism and Resistance to Cell Death: Novel Therapeutic Perspectives 2nd Edition

Guest Editor:

Dr. Francesco Ciccarese

Istituto Oncologico Veneto IOV-
IRCCS, via Gattamelata 64, 35128
Padova, Italy

Deadline for manuscript
submissions:

closed (30 June 2024)

Message from the Guest Editor

Metabolic rewiring is a common feature of cancer cells which promotes tumorigenesis by sustaining uncontrolled proliferation, survival in an adverse microenvironment, invasion, metastasis and resistance to anticancer therapies. Cancer cells tightly control catabolic and anabolic reactions through a plethora of processes, including oncogenic activation, loss of tumor suppressors, genetic alterations in metabolic genes, epigenetic regulation and modulation by both microRNAs and long non-coding RNAs. The pivotal role of metabolic reprogramming in the resistance of cancer cells to different types of cell death, including apoptosis and ferroptosis, provides the rationale for anticancer strategies aimed at rewiring cancer cell metabolism. Such approaches have the potential to enhance the sensitivity of cancer cells to conventional and targeted therapies. This Special Issue of *Biomedicines* aims at dissecting the multifaceted connections between cancer metabolism and cell death pathways, with a focus on the pharmacological modulation of tumor metabolism as an anticancer strategy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)